Trial Profile
Phase II Trial of Ixazomib Combined With Gemcitabine and Doxorubicin in Patients With Renal Medullary Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Gemcitabine (Primary) ; Ixazomib (Primary)
- Indications Renal cancer; Renal cell carcinoma
- Focus Therapeutic Use
- 08 Jan 2024 Planned End Date changed from 31 Jan 2024 to 31 Jan 2025.
- 08 Jan 2024 Planned primary completion date changed from 31 Jan 2024 to 31 Jan 2025.
- 08 Jan 2024 Status changed from recruiting to active, no longer recruiting.